199 related articles for article (PubMed ID: 25311916)
1. The effect of polymorphic metabolism enzymes on serum phenytoin level.
Ozkaynakci A; Gulcebi MI; Ergeç D; Ulucan K; Uzan M; Ozkara C; Guney I; Onat FY
Neurol Sci; 2015 Mar; 36(3):397-401. PubMed ID: 25311916
[TBL] [Abstract][Full Text] [Related]
2. CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.
Ortega-Vázquez A; Dorado P; Fricke-Galindo I; Jung-Cook H; Monroy-Jaramillo N; Martínez-Juárez IE; Familiar-López I; Peñas-Lledó E; LLerena A; López-López M
Pharmacogenomics J; 2016 Jun; 16(3):286-92. PubMed ID: 26122019
[TBL] [Abstract][Full Text] [Related]
3. The association between CYP2C9/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: A systematic review and meta-analysis
.
Liao K; Liu Y; Ai CZ; Yu X; Li W
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):337-346. PubMed ID: 29628024
[TBL] [Abstract][Full Text] [Related]
4. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
Huang Y; Yang JF; Qi XL; Wang YQ; Wang WZ; Chen B
Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1686-9. PubMed ID: 15569425
[TBL] [Abstract][Full Text] [Related]
5. CYP2C9 (*2&*3) and CYP2C19 (*2&*3) polymorphisms among children with nonlesional epilepsy: a single-center study.
Eltalal S; El Ayouty M; El-Said A; Wahba Y
Acta Neurol Belg; 2021 Dec; 121(6):1623-1631. PubMed ID: 32683556
[TBL] [Abstract][Full Text] [Related]
6. Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.
Chaudhary N; Kabra M; Gulati S; Gupta YK; Pandey RM; Bhatia BD
BMC Pediatr; 2016 May; 16():66. PubMed ID: 27179628
[TBL] [Abstract][Full Text] [Related]
7. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
[TBL] [Abstract][Full Text] [Related]
8. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
van der Weide J; Steijns LS; van Weelden MJ; de Haan K
Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
[TBL] [Abstract][Full Text] [Related]
9. Phenytoin intoxication associated with omeprazole administration in a child with defective CYP2C9.
Marano M; Nicoletti F; Pro S; Goffredo BM; Cecchetti C; Piervincenzi E; Agolini E; Cocciadiferro D
Eur J Clin Pharmacol; 2020 May; 76(5):731-732. PubMed ID: 31938857
[TBL] [Abstract][Full Text] [Related]
10. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
Franco V; Perucca E
Expert Opin Drug Metab Toxicol; 2015; 11(8):1269-79. PubMed ID: 26037375
[TBL] [Abstract][Full Text] [Related]
11. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.
Lee SY; Lee ST; Kim JW
J Biochem Mol Biol; 2007 May; 40(3):448-52. PubMed ID: 17562299
[TBL] [Abstract][Full Text] [Related]
12. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
[TBL] [Abstract][Full Text] [Related]
13. Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin-Induced Cutaneous Adverse Drug Reactions.
Fohner AE; Rettie AE; Thai KK; Ranatunga DK; Lawson BL; Liu VX; Schaefer CA
Clin Transl Sci; 2020 Sep; 13(5):1004-1009. PubMed ID: 32216088
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of effects of
Kanjanasilp J; Sawangjit R; Phanthaisong S; Borihanthanawuth W
Pharmacogenomics; 2021 Jul; 22(10):629-640. PubMed ID: 34060344
[No Abstract] [Full Text] [Related]
15. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy].
Yamamoto Y; Takahashi Y; Nishimura S; Ikumi Y; Mishima N; Kagawa Y
Yakugaku Zasshi; 2011; 131(5):809-15. PubMed ID: 21532277
[TBL] [Abstract][Full Text] [Related]
16. CYP2C9 and CYP2C19 Allele and Haplotype Distributions in Four Mestizo Populations from Western Mexico: An Interethnic Comparative Study.
Saldaña-Cruz AM; León-Moreno LC; Sánchez-Corona J; Santiago DA; Mendoza-Carrera F; Castro-Martínez XH; García-Zapién AG; Morán-Moguel MC; Flores-Martínez SE
Genet Test Mol Biomarkers; 2016 Nov; 20(11):702-709. PubMed ID: 27617498
[TBL] [Abstract][Full Text] [Related]
17. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.
Hung CC; Lin CJ; Chen CC; Chang CJ; Liou HH
Ther Drug Monit; 2004 Oct; 26(5):534-40. PubMed ID: 15385837
[TBL] [Abstract][Full Text] [Related]
18. Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs.
Taur SR; Kulkarni NB; Gandhe PP; Thelma BK; Ravat SH; Gogtay NJ; Thatte UM
J Postgrad Med; 2014; 60(3):265-9. PubMed ID: 25121365
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance.
Kousar S; Wafai ZA; Wani MA; Jan TR; Andrabi KI
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):504-16. PubMed ID: 25943175
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP2C9 genetic polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients.
Ramasamy K; Narayan SK; Shewade DG; Chandrasekaran A
Ther Drug Monit; 2010 Dec; 32(6):762-6. PubMed ID: 21068649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
